Evaluation of Multiple Potential Pharmacogenomic Risk Factors for Chronic Mefloquine Neurotoxicity through the Establishment of a Drug Safety Registry

Abstract

The purpose of this study is to investigate possible pharmacogenomic risk factors for mefloquine neurotoxicity and potentially find markers that may differentiate between mefloquine toxicity and PTSD. This study is a pilot study powered to find large, clinically significant differences in genetic variants along with exploratory objectives aimed at looking for trends in symptom complexes, environmental interactions with various genetic markers and differences between mefloquine toxicity and PTSD. The subject population includes anyone with a mefloquine exposure history or diagnosis of PTSD without mefloquine exposure. The study is a cross-sectional case-control study. The protocol has been approved by the USUHS IRB and the business contract is currently being reviewed.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Jun 01, 2021
Accession Number
AD1144337

Entities

People

  • Jeffrey Livezey

Organizations

  • Uniformed Services University of the Health Sciences

Tags

Communities of Interest

  • Biomedical

DTIC Thesaurus Topics

  • Biomedical Research
  • Covid-19
  • Data Analysis
  • Department Of Defense
  • Diseases And Disorders
  • Genetic Markers
  • Information Operations
  • Maryland
  • Patent Applications
  • Professional Development
  • Risk
  • Risk Factors
  • Students
  • Technology Transfer
  • Test And Evaluation
  • Toxicity
  • Universities

Readers

  • Mental Health of Military Veterans with Posttraumatic Stress Disorder (PTSD): Risk Factors, Prevalence, Symptoms, and Treatment.
  • Parasitology and Pharmacology of Malaria.
  • Systems Analysis and Design

Technology Areas

  • Biotechnology